Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet (R)/Dovobet (R)/Taclonex (R)) in the treatment of psoriasis vulgaris
(2006) In Dermatology 213(4). p.319-326- Abstract
- Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a... (More)
- Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a difference between treatments from the overall treatment effect for the percentage of satisfactory responses for each patient during the study (p = 0.071). This appeared to be due to the comparison of the two-compound and calcipotriol groups (p = 0.025). Conclusion: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/685631
- author
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Taclonex (R), Dovobet (R), Daivobet (R), psoriasis, two-compound product
- in
- Dermatology
- volume
- 213
- issue
- 4
- pages
- 319 - 326
- publisher
- Karger
- external identifiers
-
- wos:000242372000009
- scopus:33751532623
- pmid:17135738
- ISSN
- 1421-9832
- DOI
- 10.1159/000096069
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pediatrics/Urology/Gynecology/Endocrinology (013240400)
- id
- 49f15a71-98d5-4075-be8f-89930116a009 (old id 685631)
- date added to LUP
- 2016-04-01 11:59:01
- date last changed
- 2022-04-28 22:50:34
@article{49f15a71-98d5-4075-be8f-89930116a009,
abstract = {{Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a difference between treatments from the overall treatment effect for the percentage of satisfactory responses for each patient during the study (p = 0.071). This appeared to be due to the comparison of the two-compound and calcipotriol groups (p = 0.025). Conclusion: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol.}},
author = {{Kragballe, K. and Austad, J. and Barnes, L. and Bibby, A. and de la Brassinne, M. and Cambazard, F. and Fleming, C. and Heikkila, H. and Williams, Z. and Rey, J. Peyri and Svensson, Åke and Toole, J. and Wozel, G.}},
issn = {{1421-9832}},
keywords = {{Taclonex (R); Dovobet (R); Daivobet (R); psoriasis; two-compound product}},
language = {{eng}},
number = {{4}},
pages = {{319--326}},
publisher = {{Karger}},
series = {{Dermatology}},
title = {{Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet (R)/Dovobet (R)/Taclonex (R)) in the treatment of psoriasis vulgaris}},
url = {{http://dx.doi.org/10.1159/000096069}},
doi = {{10.1159/000096069}},
volume = {{213}},
year = {{2006}},
}